Imunon(IMNN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 7, 2024 – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three and nine months ended September 30, 2024. The Company also provided an update on its clinical development of IMNN-001 including progress toward commencing a Phase 3 study in adva ...